Skin Cancer/Melanoma
FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma
BY JASON M. BRODERICK
Exploring the Need for Better Melanoma Surveillance
BY BRIELLE URCIUOLI
FDA Approves Adjuvant Treatment Combination for Patients With BRAF+ Melanoma
BY JASON M. BRODERICK
FDA Grants Priority Review to Cemiplimab for Treatment of Metastatic CSCC
BY JASON M. BRODERICK
Merkel Cell Cancer on the Rise
BY LISA SCHULMEISTER, MN, RN, FAAN
Adjuvant Pembrolizumab Improves Recurrence-Free Survival in Melanoma
BY JASON M. BRODERICK
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors
BY KRISTIE L. KAHL
Updated Skin Cancer Prevention Guidelines
BY LISA SCHULMEISTER, MN, RN, ACNS-BC, FAAN
FDA Approves 4-Week Dosing Schedule for Nivolumab
BY JASON M. BRODERICK
Younger Cancer Survivors Put Themselves at Risk When They Fail to Seek Follow-Up Care
BY BETH FAND INCOLLINGO
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.